Bluevac BTV (previously Bluevac BTV8)

RSS

Authorised

This medicine is authorised for use in the European Union

MedicineVeterinaryAuthorised

Czech is available via eTranslation, the European Commission's machine translation service.

Translate to Czech | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

български (BG) (93.36 KB - PDF)

Zobrazit

español (ES) (81.97 KB - PDF)

Zobrazit

čeština (CS) (93.99 KB - PDF)

Zobrazit

dansk (DA) (83.34 KB - PDF)

Zobrazit

Deutsch (DE) (82.76 KB - PDF)

Zobrazit

eesti (ET) (82.18 KB - PDF)

Zobrazit

ελληνικά (EL) (93.76 KB - PDF)

Zobrazit

français (FR) (82.44 KB - PDF)

Zobrazit

Gaeilge (GA) (83.57 KB - PDF)

Zobrazit

hrvatski (HR) (92.27 KB - PDF)

Zobrazit

italiano (IT) (82.29 KB - PDF)

Zobrazit

latviešu (LV) (94.29 KB - PDF)

Zobrazit

lietuvių (LT) (94.03 KB - PDF)

Zobrazit

magyar (HU) (94.15 KB - PDF)

Zobrazit

Malti (MT) (95.95 KB - PDF)

Zobrazit

Nederlands (NL) (82.05 KB - PDF)

Zobrazit

polski (PL) (95.62 KB - PDF)

Zobrazit

português (PT) (83.01 KB - PDF)

Zobrazit

română (RO) (94.17 KB - PDF)

Zobrazit

slovenčina (SK) (94.08 KB - PDF)

Zobrazit

slovenščina (SL) (82.27 KB - PDF)

Zobrazit

suomi (FI) (81.54 KB - PDF)

Zobrazit

svenska (SV) (82.05 KB - PDF)

Zobrazit

Íslenska (IS) (83.29 KB - PDF)

Zobrazit

norsk (NO) (82 KB - PDF)

Zobrazit

Product information

български (BG) (91.78 KB - PDF)

Zobrazit

español (ES) (81.51 KB - PDF)

Zobrazit

čeština (CS) (92.48 KB - PDF)

Zobrazit

dansk (DA) (82.05 KB - PDF)

Zobrazit

Deutsch (DE) (81.72 KB - PDF)

Zobrazit

eesti (ET) (81.22 KB - PDF)

Zobrazit

ελληνικά (EL) (91.79 KB - PDF)

Zobrazit

français (FR) (81.63 KB - PDF)

Zobrazit

Gaeilge (GA) (81.36 KB - PDF)

Zobrazit

hrvatski (HR) (91.56 KB - PDF)

Zobrazit

italiano (IT) (81.76 KB - PDF)

Zobrazit

latviešu (LV) (92.14 KB - PDF)

Zobrazit

lietuvių (LT) (92.19 KB - PDF)

Zobrazit

magyar (HU) (92.76 KB - PDF)

Zobrazit

Malti (MT) (93.86 KB - PDF)

Zobrazit

Nederlands (NL) (81.15 KB - PDF)

Zobrazit

polski (PL) (93.22 KB - PDF)

Zobrazit

português (PT) (82.53 KB - PDF)

Zobrazit

română (RO) (91.73 KB - PDF)

Zobrazit

slovenčina (SK) (81.75 KB - PDF)

Zobrazit

slovenščina (SL) (81.76 KB - PDF)

Zobrazit

suomi (FI) (81.11 KB - PDF)

Zobrazit

svenska (SV) (81.47 KB - PDF)

Zobrazit

Íslenska (IS) (81.52 KB - PDF)

Zobrazit

norsk (NO) (81.52 KB - PDF)

Zobrazit

български (BG) (93.36 KB - PDF)

Zobrazit

español (ES) (81.97 KB - PDF)

Zobrazit

čeština (CS) (93.99 KB - PDF)

Zobrazit

dansk (DA) (83.34 KB - PDF)

Zobrazit

Deutsch (DE) (82.76 KB - PDF)

Zobrazit

eesti (ET) (82.18 KB - PDF)

Zobrazit

ελληνικά (EL) (93.76 KB - PDF)

Zobrazit

français (FR) (82.44 KB - PDF)

Zobrazit

Gaeilge (GA) (83.57 KB - PDF)

Zobrazit

hrvatski (HR) (92.27 KB - PDF)

Zobrazit

italiano (IT) (82.29 KB - PDF)

Zobrazit

latviešu (LV) (94.29 KB - PDF)

Zobrazit

lietuvių (LT) (94.03 KB - PDF)

Zobrazit

magyar (HU) (94.15 KB - PDF)

Zobrazit

Malti (MT) (95.95 KB - PDF)

Zobrazit

Nederlands (NL) (82.05 KB - PDF)

Zobrazit

polski (PL) (95.62 KB - PDF)

Zobrazit

português (PT) (83.01 KB - PDF)

Zobrazit

română (RO) (94.17 KB - PDF)

Zobrazit

slovenčina (SK) (94.08 KB - PDF)

Zobrazit

slovenščina (SL) (82.27 KB - PDF)

Zobrazit

suomi (FI) (81.54 KB - PDF)

Zobrazit

svenska (SV) (82.05 KB - PDF)

Zobrazit

Íslenska (IS) (83.29 KB - PDF)

Zobrazit

norsk (NO) (82 KB - PDF)

Zobrazit

Product details

Name of medicine
Bluevac BTV (previously Bluevac BTV8)
Active substance
bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated]

Pharmacotherapeutic group

  • Immunologicals for Ovidae
  • Immunologicals for Bovidae
  • Inactivated viral vaccines

Authorisation details

EMA product number
EMEA/V/C/000156

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Assessment history

This page was last updated on

Share this page